Alpha-1 antitrypsin deficiency is a rare genetic condition that can lead to lung disease in infants, children, and adults. Adult lung disease is treated by FDA-approved augmentation therapies which consist of weekly intravenous infusions made from the collection of plasma from healthy donors. The John W. Walsh Home Infusion Act (H.R.2343) would allow Medicare beneficiaries with Alpha-1 to receive their weekly infusion treatments from the comfort of their own homes. This would mitigate the risk of contracting an illness while visiting a hospital for treatment, reduce the burden of securing transportation to and from their appointments, and ensure equitable treatment coverage for home infusion alongside Medicaid and other government and commercial insurance programs.

Tell your member of Congress to cosponsor the John W. Walsh Home Infusion Act (H.R.2343) today!